Market Overview

Novartis: Q3 Earnings Insights



Shares of Novartis (NYSE:NVS) decreased 1.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 7.80% year over year to $1.52, which beat the estimate of $1.45.

Revenue of $12,259,000,000 rose by 0.71% year over year, which missed the estimate of $12,530,000,000.


Novartis hasn't issued any earnings guidance for the time being.

Novartis hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Oct 27, 2020

Time: 09:00 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $99.84

52-week low: $69.18

Price action over last quarter: down 4.24%

Company Profile

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.


Related Articles (NVS)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at